Tackling hepatitis B virus-associated hepatocellular carcinoma--the future is now. (Q38056849)

27 August 2017

title

Tackling hepatitis B virus-associated hepatocellular carcinoma--the future is now. (English)

1 reference

27 August 2017

1 reference

Mausumi Bharadwaj

1

1 reference

27 August 2017

Gaurav Roy

2

1 reference

27 August 2017

Koushik Dutta

3

1 reference

27 August 2017

Mohammad Misbah

4

1 reference

27 August 2017

Mohammad Husain

5

1 reference

27 August 2017

Showket Hussain

6

1 reference

27 August 2017

publication date

1 June 2013

1 reference

Cancer and Metastasis Reviews

27 August 2017

published in

1 reference

27 August 2017

volume

32

1 reference

27 August 2017

issue

1-2

1 reference

27 August 2017

page(s)

229-268

1 reference

Hepatocellular carcinoma pathogenesis: from genes to environment

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Genomics and signaling pathways in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Hepatocellular carcinoma--epidemiological trends and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Hepatitis-B virus infection in black children with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Comparison of clinical features and survival in patients with hepatitis B and C virus-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Influence of hepatitis b virus infection and age on mode of growth of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Metastatic hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Transforming growth factor-beta signaling promotes hepatocarcinogenesis induced by p53 loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Epidemiology of primary liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Prospects for hepatitis B virus eradication and control of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Relative risks of death due to liver disease among Japanese male adults having various statuses for hepatitis B s and e antigen/antibody in serum: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Natural history and prognostic factors for chronic hepatitis type B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Profile of hepatocellular carcinoma in India: an insight into the possible etiologic associations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Risk factors analysis for hepatocellular carcinoma in patients with and without cirrhosis: a case-control study of 213 hepatocellular carcinoma patients from India.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Hepatitis B and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Estimating the world cancer burden: Globocan 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Global cancer statistics, 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Novel concepts in hepatocellular carcinoma: from molecular research to clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Hepatitis B virus X protein enhances androgen receptor-responsive gene expression depending on androgen level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Molecular mechanisms in hepatocellular carcinoma development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Prognostic molecular markers in hepatocellular carcinoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Association of tumor necrosis factor-alpha gene promoter polymorphisms with acute viral hepatitis in the Indian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Association of TNF-alpha promoter polymorphisms with the outcomes of hepatitis B virus infection in Chinese Han population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Association of TNF-alpha genetic polymorphisms with hepatocellular carcinoma susceptibility: a case-control study in a Han Chinese population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Management of hepatocellular carcinoma: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Alpha-1-acid glycoprotein as potential biomarker for alpha-fetoprotein-low hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Clinical utility of prothrombin induced by vitamin K absence in the detection of hepatocellular carcinoma in Indian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Mutational complex genotype of the hepatitis B virus X /precore regions as a novel predictive marker for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Randomized controlled trial of screening for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Viral pathogenesis of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Low frequency of p53 mutations observed in a diverse collection of primary hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Integration of hepatitis B virus DNA in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Activation of c-myc by woodchuck hepatitis virus insertion in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Molecular events in the pathogenesis of hepadnavirus-associated hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Hepatitis B virus pre-S mutants, endoplasmic reticulum stress and hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Nucleotide change of codon 38 in the X gene of hepatitis B virus genotype C is associated with an increased risk of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Leaky transcription termination produces larger and smaller than genome size hepatitis B virus X gene transcripts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Analysis of the X gene promoter of woodchuck hepatitis virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

X Region Deletion Variants of Hepatitis B Virus in Surface Antigen-Negative Infections and Non-A, Non-B Hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Hepatitis B virus X gene 1751 to 1764 mutations: implications for HBeAg status and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Hepatitis B and C virus-related carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Characterisation of hepatitis B virus X protein mutants in tumour and non-tumour liver cells using laser capture microdissection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

COOH-terminal truncated HBV X protein plays key role in hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Association of human APOBEC3 cytidine deaminases with the generation of hepatitis virus B x antigen mutants and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

The enigmatic X gene of hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Selective transcriptional regulations in the human liver cell by hepatitis B viral X protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

The hepatitis B virus HBx protein inhibits caspase 3 activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

HBXIP functions as a cofactor of survivin in apoptosis suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

X protein of hepatitis B virus inhibits Fas-mediated apoptosis and is associated with up-regulation of the SAPK/JNK pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Activated ras oncogene collaborates with HBx gene of hepatitis B virus to transform cells by suppressing HBx-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

The hepatitis B virus-X protein activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

X-gene product of hepatitis B virus induces apoptosis in liver cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Hepatitis B virus X protein induces apoptosis in hepatoma cells through inhibiting Bcl-xL expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Hepatitis B virus X protein via the p38MAPK pathway induces E2F1 release and ATR kinase activation mediating p53 apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

To be, or not to be: NF-kappaB is the answer--role of Rel/NF-kappaB in the regulation of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Effects of hepatitis B virus X protein on the development of liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Erk-independent partial activation of AP-1 sites by the hepatitis B virus HBx protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Src kinases involved in hepatitis B virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Hepatitis B virus X protein activates the p38 mitogen-activated protein kinase pathway in dedifferentiated hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Signal transducers and activators of transcription 5b activation enhances hepatocellular carcinoma aggressiveness through induction of epithelial-mesenchymal transition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Mitochondrially associated hepatitis B virus X protein constitutively activates transcription factors STAT-3 and NF-kappa B via oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Shaping the nuclear action of NF-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Hepatitis B virus X protein protects against anti-Fas-mediated apoptosis in human liver cells by inducing NF-kappa B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Hepatitis B virus protein X-induced expression of the CXC chemokine IP-10 is mediated through activation of NF-kappaB and increases migration of leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Hepatitis B virus X protein drives multiple cross-talk cascade loops involving NF-κB, 5-LOX, OPN and Capn4 to promote cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Hepatitis B virus X protein blunts senescence-like growth arrest of human hepatocellular carcinoma by reducing Notch1 cleavage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Hepatitis B virus X protein stimulates the Hedgehog-Gli activation through protein stabilization and nuclear localization of Gli1 in liver cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Dysregulation of β-catenin by hepatitis B virus X protein in HBV-infected human hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Telomeres, telomerase and cancer: an up-date

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Effects of hepatitis B virus X protein on human telomerase reverse transcriptase expression and activity in hepatoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

X protein of hepatitis B virus functions as a transcriptional corepressor on the human telomerase promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Tetraploidy, aneuploidy and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

A promiscuous alpha-helical motif anchors viral hijackers and substrate receptors to the CUL4-DDB1 ubiquitin ligase machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Hepatitis B virus X protein increases the Cdt1-to-geminin ratio inducing DNA re-replication and polyploidy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Polo-like kinase 1 inhibition suppresses hepatitis B virus X protein-induced transformation in an in vitro model of liver cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Proteins ZNF198 and SUZ12 are down-regulated in hepatitis B virus (HBV) X protein-mediated hepatocyte transformation and in HBV replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Defective DNA strand break repair causes chromosomal instability and accelerates liver carcinogenesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Accelerated carcinogenesis following liver regeneration is associated with chronic inflammation-induced double-strand DNA breaks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

HBx gene of hepatitis B virus induces liver cancer in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Induction of cell cycle progression by hepatitis B virus HBx gene expression in quiescent mouse fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

The hepatitis B virus X protein sensitizes HepG2 cells to UV light-induced DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Hepatitis B virus X protein impedes the DNA repair via its association with transcription factor, TFIIH

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Hepatitis B viral X protein alters the biological features and expressions of DNA repair enzymes in LO2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Hepatitis B virus X protein promotes hepatoma cell invasion and metastasis by stabilizing Snail protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

C-terminal truncated hepatitis B virus x protein is associated with metastasis and enhances invasiveness by C-Jun/matrix metalloproteinase protein 10 activation in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Upregulated FoxM1 expression induced by hepatitis B virus X protein promotes tumor metastasis and indicates poor prognosis in hepatitis B virus-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

The hepatitis B virus X protein (HBx) induces a migratory phenotype in a CD44-dependent manner: possible role of HBx in invasion and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

p73 tumor suppressor protein: a close relative of p53 not only in structure but also in anti-cancer approach?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Dissection of cell context-dependent interactions between HBx and p53 family members in regulation of apoptosis: a role for HBV-induced HCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Does the hepatitis B antigen HBx promote the appearance of liver cancer stem cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

The X protein of hepatitis B virus inhibits apoptosis in hepatoma cells through enhancing the methionine adenosyltransferase 2A gene expression and reducing S-adenosylmethionine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Hepatitis B virus genotype distribution among chronic hepatitis B virus carriers in Shanghai, China

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Genetics of hepatocellular tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Pivotal role of mTOR signaling in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Dysregulation of growth factor signaling in human hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Growth and spread of hepatocellular carcinoma. A review of 240 consecutive autopsy cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Ferumoxide-enhanced MR imaging of hepatocellular carcinoma: correlation with histologic tumor grade and tumor vascularity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Prediction of recurrence and extratumor spread of hepatocellular carcinoma following resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Extrahepatic spread from hepatocellular carcinoma: who are candidates for aggressive anti-cancer treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Primary liver cancer: pattern of metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Metastatic hepatocellular carcinoma in the tympanic membrane.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Metastasis to the appendix from a hepatocellular carcinoma manifesting as acute appendicitis: CT findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

A rare occurrence of hepatocellular carcinoma metastasis to the mandible: report of a case and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

A patient with spinal metastasis from hepatocellular carcinoma discovered from neurological findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Gallbladder metastasis from hepatocellular carcinoma: Report of a case and review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Solitary Asymptomatic Thyroid Metastasis from Hepatocellular Carcinoma Detected by FDG-PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Oral metastasis of a hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Skull metastasis from hepatocellular carcinoma with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Clinical features of hepatocellular carcinoma with extrahepatic metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Hepatocellular carcinoma: insight from animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Proteomic analysis of liver tissue from HBx-transgenic mice at early stages of hepatocarcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

HBsAg and HBx knocked into the p21 locus causes hepatocellular carcinoma in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

The up-regulation of proteasome subunits and lysosomal proteases in hepatocellular carcinomas of the HBx gene knockin transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

A transgenic mouse model of the chronic hepatitis B surface antigen carrier state

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Experimental models of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Thalidomide in cancer medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

DNA methylation and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Radiofrequency ablation of liver tumors: influence of technique and tumor size

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Hepatocellular carcinoma: systemic treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Mechanisms of HBV-related hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

The global impact of vaccination against hepatitis B: a historical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

The global health burden of infection-associated cancers in the year 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Focus on hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Effect of viral status on recurrence after liver resection for patients with hepatitis B virus-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Clinical features of hepatitis B virus-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Surgical treatment for early hepatocellular carcinoma: comparison of resection and liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Molecular therapy for the treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Targeted therapies for hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Molecular targeted therapies in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Emerging roles of microRNA in the intracellular signaling networks of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Could HBx protein expression affect signal pathway inhibition by gefitinib or selumetinib, a MEK inhibitor, in hepatocellular carcinoma cell lines?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Influence of levothyroxine treatment on serum levels of soluble Fas (CD95) and Fas Ligand (CD95L) in chronic autoimmune hypothyroidism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Knockdown of HBV surface antigen gene expression by a lentiviral microRNA-based system inhibits HBV replication and HCC growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Blocking peptides against HBV: preS1 protein selected from a phage display library

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Antisense oligonucleotides targeting abhydrolase domain containing 2 block human hepatitis B virus propagation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Role of transforming growth factor beta in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

TGF beta signals through a heteromeric protein kinase receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Regulation of transforming growth factor-beta 1 expression by the hepatitis B virus (HBV) X transactivator. Role in HBV pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

The effect of hepatitis B virus X gene expression on response to growth inhibition by transforming growth factor-beta 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

TGF-beta inhibitors for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Kinase activation profile associated with TGF-β-dependent migration of HCC cells: a preclinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

RNA Interference as Therapeutics for Hepatocellular Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Disruption of Dicer1 induces dysregulated fetal gene expression and promotes hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

A decade's studies on metastasis of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

A novel inhibitor of human La protein with anti-HBV activity discovered by structure-based virtual screening and in vitro evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Identification of LZAP as a new candidate tumor suppressor in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Tumor suppressor protein C53 antagonizes checkpoint kinases to promote cyclin-dependent kinase 1 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

A novel ARF-binding protein (LZAP) alters ARF regulation of HDM2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

ShRNA-targeted centromere protein A inhibits hepatocellular carcinoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

ShRNA-targeted MAP4K4 inhibits hepatocellular carcinoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Molecular and serum markers in hepatocellular carcinoma: predictive tools for prognosis and recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

The present and the future landscape of treatment of advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-012-9412-6

Could antiplatelet drugs be used to prevent HBV-associated hepatocellular carcinoma?

21 January 2018

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/citations/10.1038/NRGASTRO.2012.139

Identifiers

DOI

10.1007/S10555-012-9412-6

1 reference

Dimensions Publication ID

27 August 2017

1032089951

0 references

1 reference